TrialBMC nephrology2021

Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.

Anja Gäckler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.